Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS-III trial demonstrates improved liver function in patients. These patients did not respond to standard treatment. Zydus plans to seek US regulatory approval in early 2026. Saroglitazar is a novel treatment option. It addresses bile acid toxicity and liver inflammation.